Free Trial

Olema Pharmaceuticals (OLMA) News Today

Olema Pharmaceuticals logo
$4.96 -0.19 (-3.69%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$5.19 +0.23 (+4.64%)
As of 05/28/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OLMA Latest News

Olema Pharmaceuticals, Inc. stock logo
BNP Paribas Financial Markets Makes New $1.13 Million Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
BNP Paribas Financial Markets acquired a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 193,748 shares of the company's st
Olema Pharmaceuticals, Inc. stock logo
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Acquired by MPM Bioimpact LLC
MPM Bioimpact LLC increased its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 8.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,912,550 shares of the company's stock aft
Olema Pharmaceuticals, Inc. stock logo
Paradigm Biocapital Advisors LP Buys 1,801,370 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Paradigm Biocapital Advisors LP increased its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 32.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,3
Olema Pharmaceuticals, Inc. stock logo
Lightspeed Management Company L.L.C. Makes New Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Lightspeed Management Company L.L.C. bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,930,894 shares of
Olema Pharmaceuticals, Inc. stock logo
Driehaus Capital Management LLC Takes Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Driehaus Capital Management LLC bought a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 220,264 shares o
Olema Pharmaceuticals, Inc. stock logo
Balyasny Asset Management L.P. Buys 418,492 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Balyasny Asset Management L.P. increased its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 59.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,127,589 shares of the company's s
Olema Pharmaceuticals, Inc. stock logo
Olema Pharmaceuticals (OLMA) Projected to Post Earnings on Wednesday
Olema Pharmaceuticals (NASDAQ:OLMA) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-olema-pharmaceuticals-inc-stock/)
Olema Pharmaceuticals, Inc. stock logo
Deep Track Capital LP Sells 557,167 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Deep Track Capital LP reduced its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 13.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,442,833 shares of the company's stock aft
Olema Pharmaceuticals, Inc. stock logo
BVF Inc. IL Sells 3,420,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
BVF Inc. IL decreased its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 37.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 5,715,893 shares of the company's stock after selling 3,420,000 shares during
Olema Pharmaceuticals, Inc. stock logo
Boxer Capital Management LLC Invests $3.79 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Boxer Capital Management LLC purchased a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 650,000 shares of the company's stock,
Olema Pharmaceuticals, Inc. stock logo
Renaissance Technologies LLC Has $917,000 Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Renaissance Technologies LLC boosted its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 435.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 157,300 shares of the company's stock after
Olema Pharmaceuticals, Inc. stock logo
Olema Pharmaceuticals' (OLMA) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a report on Monday.
Olema Pharmaceuticals, Inc. stock logo
Walleye Capital LLC Acquires New Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Walleye Capital LLC bought a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 67,007 shares of the company's stock, valued a
Olema Pharmaceuticals, Inc. stock logo
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by Silverarc Capital Management LLC
Silverarc Capital Management LLC reduced its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 48.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 233,281 shares of the company'
Olema Pharmaceuticals, Inc. stock logo
1,651,982 Shares in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Purchased by Avoro Capital Advisors LLC
Avoro Capital Advisors LLC purchased a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,651,982 shares of the company's stock, valued at
Olema Pharmaceuticals, Inc. stock logo
Bain Capital Life Sciences Investors LLC Invests $43.55 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Bain Capital Life Sciences Investors LLC bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 7,470,214 shares of the company's stock,
Olema Pharmaceuticals, Inc. stock logo
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Short Interest Update
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) was the target of a large drop in short interest in March. As of March 31st, there was short interest totalling 6,500,000 shares, a drop of 25.2% from the March 15th total of 8,690,000 shares. Based on an average trading volume of 1,090,000 shares, the short-interest ratio is currently 6.0 days. Approximately 14.1% of the company's stock are sold short.
Olema Pharmaceuticals, Inc. stock logo
Alliancebernstein L.P. Has $1.83 Million Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Alliancebernstein L.P. increased its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 77.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 313,982 shares of the company's stock after purchasing an additional 137,3
Olema Pharmaceuticals, Inc. stock logo
Vanguard Group Inc. Grows Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Vanguard Group Inc. grew its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 6.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,685,009 shares of the
Olema Pharmaceuticals, Inc. stock logo
Franklin Resources Inc. Buys 258,625 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Franklin Resources Inc. grew its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 1,714.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 273,706 shares of the company's stock after purchasin
Olema Pharmaceuticals, Inc. stock logo
Wellington Management Group LLP Has $8.84 Million Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Wellington Management Group LLP boosted its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 52.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,525,484 shares of the company's stock after buying an additional
Olema Pharmaceuticals, Inc. stock logo
Schroder Investment Management Group Grows Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Schroder Investment Management Group grew its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 548.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 533,111 shares of the company's stock
Olema Pharmaceuticals, Inc. stock logo
Pictet Asset Management Holding SA Boosts Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Pictet Asset Management Holding SA raised its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 12.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,883,354 shares of the company's stock after buying an additi
Olema Pharmaceuticals, Inc. stock logo
HighTower Advisors LLC Takes $510,000 Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
HighTower Advisors LLC bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 87,476 shares of the company's stock, valued
Olema Pharmaceuticals, Inc. stock logo
JPMorgan Chase & Co. Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $28.00
JPMorgan Chase & Co. decreased their price objective on Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating on the stock in a report on Friday.
Olema Oncology price target lowered to $28 from $30 at JPMorgan
Olema Pharmaceuticals, Inc. stock logo
Pier Capital LLC Invests $1.59 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Pier Capital LLC purchased a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 272,372 shares of the company's stock, valued at approximately $1,588,000. Pi
Olema Pharmaceuticals, Inc. stock logo
FY2025 Earnings Estimate for OLMA Issued By Lifesci Capital
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Analysts at Lifesci Capital cut their FY2025 EPS estimates for shares of Olema Pharmaceuticals in a research report issued on Wednesday, March 19th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings per s
Olema Pharmaceuticals, Inc. stock logo
HC Wainwright Issues Optimistic Estimate for OLMA Earnings
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst E. Bodnar now anticipates that th
Olema Pharmaceuticals, Inc. stock logo
Victory Capital Management Inc. Sells 758,412 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Victory Capital Management Inc. trimmed its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 89.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 93,100 shares of the company's stock after selling 758,412 shares during the per
Olema Pharmaceuticals, Inc. stock logo
What is HC Wainwright's Forecast for OLMA FY2029 Earnings?
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - HC Wainwright issued their FY2029 EPS estimates for Olema Pharmaceuticals in a report released on Wednesday, March 19th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($2.41) per share for the year. HC Wa
Olema Pharmaceuticals, Inc. stock logo
Olema Pharmaceuticals (NASDAQ:OLMA) Given "Outperform" Rating at Oppenheimer
Oppenheimer reiterated an "outperform" rating and issued a $25.00 price objective (down previously from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday.
Olema Pharmaceuticals, Inc. stock logo
Olema Pharmaceuticals (NASDAQ:OLMA) Receives Buy Rating from HC Wainwright
HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday.
Olema Pharmaceuticals, Inc. stock logo
Olema Pharmaceuticals (NASDAQ:OLMA) Issues Earnings Results, Beats Expectations By $0.12 EPS
Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.12.
Olema Pharmaceuticals, Inc. stock logo
Olema Pharmaceuticals (NASDAQ:OLMA) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS
Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.12.
Olema Oncology price target lowered to $25 from $30 at Oppenheimer
Olema Pharmaceuticals, Inc. stock logo
Olema Pharmaceuticals (NASDAQ:OLMA) Earns "Buy" Rating from HC Wainwright
HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday.
Olema updated palazestrant combination trial, says Oppenheimer
Get Olema Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.

OLMA Media Mentions By Week

OLMA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

OLMA
News Sentiment

1.13

0.87

Average
Medical
News Sentiment

OLMA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

OLMA Articles
This Week

3

3

OLMA Articles
Average Week

Get Olema Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:OLMA) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners